Biocon is currently trading at Rs. 508.55, up by 6.50 points or 1.29% from its previous closing of Rs. 502.05 on the BSE.
The scrip opened at Rs. 504.00 and has touched a high and low of Rs. 512.00 and Rs. 502.70 respectively. So far 1,32,000 shares were traded on the counter.
The BSE group 'A ' stock of face value Rs. 5 has touched a 52 week high of Rs. 553.70 on 04-Jul-2014 and a 52 week low of Rs. 319.00 on 17-Sep-2013.
Last one week high and low of the scrip stood at Rs. 512.00 and Rs. 479.30 respectively. The current market cap of the company is Rs. 10,171.00 crore.
The promoters holding in the company stood at 60.97% while Institutions and Non-Institutions held 20.05% and 18.97% respectively.
Biocon’s wholly owned subsidiary - Biocon Research (BRL), has entered into an agreement with GE Equity International Mauritius, a subsidiary of GE Capital Corporation (GE Capital), to purchase the latter’s investment in Biocon’s research services subsidiary, Syngene International for an agreed consideration of Rs 215.38 crore. GE Capital had a 7.69% stake in Syngene.
Syngene offers integrated drug discovery and development services with capabilities in medicinal chemistry, biology, in vivo pharmacology and toxicology.
Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1883.15 |
| Dr. Reddys Labs. | 1365.65 |
| Cipla | 1440.45 |
| Zydus Lifesciences | 1101.70 |
| Lupin | 2366.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: